Hemodynamic Effects of Selective Dopamine Receptor Agonists in the Rat and Dog

References

• Hilditch A., Drew G. M. Peripheral Dopamine Receptor Subtypes—A Closer Look. Trends in Pharmacol. Sci. 1985; 6: 396–400
   Web of Science ®Google Scholar
• Goldberg L. I. Dopamine—Clinical Uses of an Endogenous Catecholamine. New Eng. J. Med. 1974; 29: 707–710
   Web of Science ®Google Scholar
• Hahn R. A., Wardell J. R., Sarau H. M., Ridley P. T. Characterization of the Peripheral and Central Effects of SK&F 82526, a Novel Dopamine Receptor Agonist. J. Pharmacol. Exp. Ther. 1981; 223: 305–313
   Web of Science ®Google Scholar
• Ackerman D. M., Weinstock J., Wiebelhaus V. D., Berkowitz B. A. Renal Vasodilators and Hypertension. Drug Dev. Res. 1982; 2: 283–297
   Web of Science ®Google Scholar
• Schmidt M., Imbs J. L., Giesen-Crouse E. M., Schwartz J. Effects of SK&F 82525 and SK&F 83742 on the Renal Vascular Dopamine Receptor. J. Pharmacol. 1985; 16: 15–22
   PubMedGoogle Scholar
• Ohlstein E. H., Zabko-Potapovich B., Berkowitz B. A. Studies on Vascular Dopamine Receptors with the Dopamine Receptor Agonist: SK&F 82526. J. Pharmacol. Exp. Ther. 1984; 229: 433–439
   PubMed Web of Science ®Google Scholar
• Weinstock J., Hieble J. P., Wilson J. W. The Chemistry and Pharmacology of 3-Benzazepine Derivatives. Drugs of the Future 1985; 10: 645–697
   Google Scholar
• Ohlstein E. H., Zabko-Potapovich B., Berkowitz B. A. The DA1 Receptor Agonist Fenoldopam (SK&F 82526) is Also an Alpha2-Adrenoceptor Antagonist. Europ. J. Pharmacol. 1985; 118: 321–329
   PubMed Web of Science ®Google Scholar
• Blumberg A. L., Wilson J. W., Hieble J. P. Neuroinhibitory Effects of SK&F 85174, a Novel Dopamine Receptor Agonist. J. Cardiovasc. Pharmacol. 1985; 7: 723–732
   PubMed Web of Science ®Google Scholar
• Lokhandwala M. F., Sabouni M. H. Ganglionic Dopamine Receptors as Mediators of the Inhibition of Neurogenic Vasoconstriction Produced by Fenoldopam. J. Auton. Pharmacol. 1985; 5: 301–305
   PubMedGoogle Scholar
• Shebuski R. J., Fujita T., Smith J. M., Kopaciewicz L. J., Blumberg A. L., Hieble O. P. Suppression of Sympathetic Ganglionic Neurotransmission by the Selective Dopamine-1 Receptor Agonist Fenoldopam (SK&F 82526) in the Anesthetized Dog. J. Pharmacol. Exp. Ther. 1985; 235: 735–740
   PubMed Web of Science ®Google Scholar
• Kohli J. D., Weder A. B., Goldberg L. I., Ginos J. Z. Structure Activity Relationships of N-Substituted Dopamine Derivatives as Agonists of the Dopamine Vascular and Other Cardiovascular Receptors. J. Pharmacol. Exp. Ther. 1980; 213: 370–374
   PubMed Web of Science ®Google Scholar
• Kaiser C., Jain T. Dopamine Receptors: Functions, Subtypes and Emerging Concepts. Med. Res. Quart. 1985; 5: 145–229
   PubMed Web of Science ®Google Scholar
• Huffman W. H., Hall R. F., Grant O. A., Hilson J. W., Hieble J. P., Hahn R. A. 4-(Aminoalkyl)-7-hydroxy-3(3H)-indolones, a Novel Class of Potent Presynaptic Dopamine Receptor Agonists. J. Med. Chem. 1983; 26: 933–935
   PubMed Web of Science ®Google Scholar
• Hieble J. P., Jervay C. A., Gruber F. H., Sarau H. M., Foley J. J., Wilson J. W., DeMarinis R. M. Agonist Activity of Aminoethyl-7-hydroxyindolones at Prejunctional Dopaminergic Receptors. Pharmacologist 1983; 25: 162
   Google Scholar
• Zeid R. L., Hieble J. P., DeMarinis R. M., Wilson J. W. Inhibition of Transmitter Release in Dog Vascular Tissue by a Selective D2 Agonist. Fed. Proc. 1984; 43: 1020
   Google Scholar
• Roesler J. M., McCafferty J. P., DeMarinis R. M., Matthews W. D., Hieble J. P. Characterization of the Antihypertensive Activity of SK&F 86466, a Selective Alpha-2 Antagonist, in the Rat. J. Pharmacol. Exp. Ther. 1986; 236: 1–7
   PubMed Web of Science ®Google Scholar
• Ackerman D. M., Blumberg A. L., McCafferty J. P., Sherman S., Weinstock J., Kaiser C., Berkowitz B. A. Potential Usefulness of Renal Vasodilators in Hypertension and Renal Disease: SK&F 82526. Fed. Proc. 1983; 42: 186–190
   PubMedGoogle Scholar
• McCoy C. E., Douglas F. L., Goldberg L. I. Selective Antagonism of the Hypotensive Effects of Dopamine Agonists in Spontaneously Hypertensive Rats. Hypertension 1986; 8: 298–302
   PubMed Web of Science ®Google Scholar
• Cavero I., Hicks P. E. Studies on the Transient Hypotensive Effects of Fenoldopam, a DA1 Dopamine Receptor Agonist, in Rats. Brit. J. Pharmacol. 1985; 86: 436P
   Google Scholar
• Cavero I., LeFevre-Borg F., Gomeni R. Blood Pressure Lowering Effects of N,N-di-n-Propyldopamine in Rats: Evidence for Stimulation of Peripheral Dopamine Receptors Leading to Inhibition of Sympathetic Vascular Tone. J. Pharmacol. Exp. Ther. 1981; 218: 515–524
   PubMed Web of Science ®Google Scholar
• Fennell W. H., Taylor A. A., Young J. B., Brandon T. A., Ginos J. Z., Goldberg L. I., Mitchell J. R. Propylbutyl dopamine: Hemodynamic Effects in Conscious Dogs, Normal Volunteers and Patients with Heart Failure. Circulation 1983; 67: 829–836
   PubMed Web of Science ®Google Scholar
• Cavero I., Hicks P. E., LeFevre-Borg F. Cardiovascular Profile of Quinpirole, A Selective and Specific DA2-Dopamine Receptor Agonist, In Rats. Brit. J. Pharmacol. 1985; 86: 618P
   Google Scholar
• Taylor A. A., Fennell W. H., Ruud C. O., Pool J. L., Nelson E. B., Ginos O. Z., Mitchell J. R. Propyl butyl dopamine. Mechanism of Blood Pressure Lowering in Hypertensive Patients. Hypertension 1984; 6(Suppl 1)I-40–I-45
   Google Scholar
• Kolloch R., Kobayashi K., DeQuattro V. Dopaminergic Control of Sympathetic Tone and Blood Pressure: Evidence in Primary Hypertension. Hypertension 1980; 2: 390–394
   PubMed Web of Science ®Google Scholar
• Johns D. W., Ayers C. R., Carey R. M. The Dopaminergic Agonist Bromocriptine Induced Hypotension by Venous and Arteriolar Dilation. J. Cardiovasc. Pharmacol. 1984; 6: 582–587
   PubMed Web of Science ®Google Scholar
• Francis G. S., Parks R., Cohn J. N. The Effects of Bromocriptine in Patients with Congestive Heart Failure. Am. Heart J. 1983; 106: 100–106
   PubMed Web of Science ®Google Scholar
• Carey R. M., Stote R. M., Dubb J. W., Townsend L. H., Rose C. E., Kaiser D. L. Selective Peripheral Dopamine-1 Receptor Stimulation with Fenoldopam in Human Essential Hypertension. J. Clin. Invest. 1984; 74: 2198–2207
   PubMed Web of Science ®Google Scholar
• Harvey J. N., Worth D. P., Brown J., Lee M. R. Studies with Fenoldopam, a Dopamine Receptor DA1 Agonist, in Essential Hypertension. Brit. J. Clin. Pharmacol. 1986; 21: 53–61
   PubMed Web of Science ®Google Scholar
• Ventura H. O., Messerli F. H., Frohlich E. D., Kobrin I., Oigman W., Dunn F. G., Carey R. M. Immediate Hemodynamic Effects of a Dopamine-Receptor Agonist (Fenoldopam) in Patients with Essential Hypertension. Circulation 1984; 69: 1142–1145
   PubMed Web of Science ®Google Scholar
• Hughes A., Thom S., Redman D., Sever P. Fenoldopam, a Dopamine Agonist, Induces Forearm Vasodilation by a Mechanism Independent of Sympathetic Activity. Blood Vessels 1986; 23: 77
   Google Scholar
• McCoy C., Frederickson E., Murphy M., Kotake A., Douglas F., Goldberg L. I. Effects of Dopamine (DA1) Receptor Agonist Administration in Hypertensive Patients. Hypertension 1985; 7: 848
   Web of Science ®Google Scholar
• Young J. B., Leon C. A., Pratt C. M., Suarez J. M., Aronoff R. D., Roberts R. Hemodynamic Effects of an Oral Dopamine Receptor Agonist (Fenoldopam) in Patients with Congestive Heart Failure. J. Am. Coll. Cardiol. 1985; 6: 792–796
   PubMed Web of Science ®Google Scholar
• Leon C. A., Taylor A. A., Kingry C., Norton J., Pratt C. M., Roberts R., Young J. B. Hemodynamic Effects of Selective Dopamine-1 Receptor Stimulation: Comparison of Intravenous Fenoldopam and Nitroprusside in Heart Failure Patients. J. Am. Coll. Cardiol. 1986; 7: 70A
   Web of Science ®Google Scholar
• Lokhandwala M. F., Jandhyala B. S. The Role of Sympathetic Nervous System in the Vascular Actions of Dopamine. J. Pharmacol. Exp. Ther. 1979; 210: 120–125
   PubMed Web of Science ®Google Scholar
• Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma Norepinephrine as a Guide to Prognosis in Patients with Congestive Heart Failure. New. Eng. J. Med. 1984; 311: 819–823
   PubMed Web of Science ®Google Scholar